Tempus AI (Nasdaq: TEM) has converted a trial-support relationship into prospective commercial infrastructure. The company's expanded, multi-year collaboration with Moderna (Nasdaq: MRNA) and Merck (NYSE: MRK) — building on joint efforts initiated in 2025, with financial terms undisclosed — assigns Tempus two roles in the intismeran autogene (V940/mRNA-4157) program: coordinating the collection and transfer of tumor tissue and blood samples for next-generation sequencing, and, subject to regulatory approvals, providing the sequencing services that feed the design and manufacturing of each patient's individualized treatment. The announcement lands weeks after the August 2026 Phase III readout from INTerpath-001, in which intismeran autogene plus pembrolizumab (Keytruda) met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in completely resected stage IIB–IV melanoma, with the partners planning to engage regulators on potential marketing applications.
The strategic logic is that for individualized neoantigen vaccines, the binding constraint at commercial scale is not antigen discovery but industrialized sample logistics and sequencing turnaround. Every dose is patient-specific: tumor and matched blood are sequenced, tumor-specific neoantigens are identified genomically, and an mRNA construct encoding them is manufactured for that single patient. That architecture makes a distributed, standardized, regulator-auditable sequencing network a prerequisite for launch — and makes Tempus's sequencing and logistics layer, rather than any single clinical result, the operational differentiator this deal secures.
Sequencing as Commercial Infrastructure
The deal's structure maps directly onto the regulatory path. Logistics coordination — tissue and blood collection, transfer, and NGS sample handling across treatment sites — begins now, while Tempus's sequencing services are explicitly conditioned on regulatory approvals, mirroring the partners' stated plan to engage regulators on potential marketing applications following INTerpath-001. In effect, Moderna and Merck are pre-positioning the commercial supply chain so that, if approvals arrive, the biopsy-to-vaccine pipeline is already operating rather than being built post-approval.
The operational content of that pipeline is demanding. Intismeran autogene's individualized manufacturing process requires tight coordination between resection or biopsy, sample shipment, tumor-normal sequencing, neoantigen identification, construct design, and drug-product manufacturing — a chain in which a delay or quality failure at any node stalls a single patient's therapy. Tempus's mandate covers the front half of that chain: sample logistics and standardized NGS across a multi-site network. For a sequencing-infrastructure company, embedding that capability in a launch-phase oncology product converts episodic trial revenue into volume-linked commercial revenue, though the undisclosed financial terms leave the economics unquantified.
The Neoantigen Selection Stack
Upstream of sequencing sits the computational problem the vaccine's design depends on: converting tumor-normal variant data into a prioritized set of neoantigen candidates for the mRNA construct. The tooling ecosystem around this step has matured alongside V940's clinical trajectory. ImmunoNX (December 2025) was published as a robust bioinformatics workflow specifically to support personalized neoantigen vaccine trials; pVACtools v6 (June 2026) extends an open-source suite whose latest release explicitly cites neoantigen-based vaccines reaching later-stage trials as the driver of computational identification and prioritization needs; and pVACview (2024) adds interactive visualization for the human-in-the-loop epitope selection step.
Machine-learning approaches continue to push ranking quality: TransNRank (August 2026) applies a transformer architecture to neoantigen ranking, targeting the field's chronic problems — scarce positive samples, noisy experimental data, severe class imbalance, and complex immunogenicity features — where linear regression and XGBoost baselines fail to model long-range dependencies. As V940 moves from trial toward market, such selection algorithms stop being research code and become embedded components of a regulated manufacturing process, where reproducibility, versioning, and auditability of the prediction pipeline carry the same weight as predictive accuracy.
Clinical Evidence in Melanoma
INTerpath-001 provides the pivotal dataset underpinning the commercialization push. In August 2026, Moderna and Merck reported that intismeran autogene plus Keytruda met the trial's primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB–IV melanoma — a fully resected, high-risk adjuvant population in which recurrence events are unambiguous. The companies now plan to engage regulators on potential marketing applications.
The Phase III result extends a durability signal from Phase IIb KEYNOTE-942, whose five-year follow-up showed the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% relative to Keytruda alone in resected stage III/IV melanoma. Five-year persistence matters because it addresses the central question for adjuvant neoantigen vaccines: whether vaccine-primed responses against tumor-specific neoantigens — identified through genomic sequencing of each patient's cancer — translate into durable protection rather than transient immunogenicity, and whether they add clinical benefit on top of checkpoint blockade with pembrolizumab.
What to Watch
Regulatory: the outcome of the partners' engagement with regulators on potential marketing applications for the intismeran autogene–pembrolizumab combination, and specifically whether the approved manufacturing process formally incorporates Tempus's sequencing services — the deal conditions that role on regulatory approvals, so approval language will define the commercial scope. Also monitor disclosure of the agreement's financial terms and whether the collaboration's scope extends beyond melanoma.
Operational and data: evidence that the tissue-and-blood logistics network scales to commercial biopsy volumes, and any disclosed biopsy-to-treatment turnaround metrics, which will indicate whether individualized manufacturing timelines are compatible with adjuvant treatment windows. On the evidence side, watch further data maturation from INTerpath-001, including longer follow-up and additional endpoints beyond the reported recurrence-free and distant metastasis-free survival results.
Ecosystem: the trajectory of neoantigen-selection tooling — pVACtools v6, pVACview, ImmunoNX, TransNRank — as a proxy for where regulator-facing computational standards in personalized vaccine manufacturing are converging, and any competing infrastructure deals between vaccine developers and sequencing or diagnostics providers that would test whether Tempus's position is defensible at scale.
Sources
- Source article
- ImmunoNX: a robust bioinformatics workflow to support personal… — 2025-12-09
- Epitope analysis for influenza vaccine design — 2004-08-23
- pVACtools v6: A comprehensive suite for neoantigen prediction,… — 2026-06-25
- Vaccine skepticism detection by network embedding — 2021-10-20
- pVACview: an interactive visualization tool for efficient neoa… — 2024-06-11
- The impact of Covid-19 vaccination in Aotearoa New Zealand: a … — 2024-01-18
- TransNRank: Towards Accurate Neoantigen Ranking with Transformer — 2026-08-03
- The illicit trade of COVID-19 vaccines on the dark web — 2021-02-10